

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10,575,049
				Filing Date	April 5, 2006
				First Named Inventor	David De Kretser
				Art Unit	1644
				Examiner Name	Maher M. Haddad
				Attorney Docket Number	PARA003US
Sheet	1	of	13		

[illegible]

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10,575,049
				Filing Date	April 5, 2006
				First Named Inventor	David De Kretser
				Art Unit	1644
				Examiner Name	Maheer M. Haddad
				Attorney Docket Number	PARA003US
Sheet	2	of	13		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10,575,049
				Filing Date	April 5, 2006
				First Named Inventor	David De Kretser
				Art Unit	1644
Examiner Name	Maher M. Haddad				
Sheet	3	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	17	ARTHUR M., "Fibrogenesis: Metalloproteinases and their inhibitors in liver fibrosis," <i>American Journal of Physiology - Gastrointestinal and Liver Physiology</i> , 279: G245-G249 (2000)	
	18	BARTHOLIN, et al., "FLRG, an Activin-Binding Protein, is a New Target of TGF-beta Transcription Activation Through SMAD Proteins," <i>Oncogene</i> , 20(39):5409-19 (2001)	
	19	DATE M., et al., "Differential expression of transforming growth factor p and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl4 administration," <i>Journal of Hepatology</i> , 28: 572-581 (1998)	
	20	DATE M., et al., "Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury," <i>J Hepatol.</i> , 32(2):251-260 (2000)	
	21	DOOLEY S., et al., "Expression of Smads during <i>in vitro</i> transdifferentiation of hepatic stellate cells to myofibroblasts," <i>Biochem. Biophys. Res. Comm.</i> , 283:554-562 (2001)	
	22	ENGELSE M., et al., "Human activin A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells," <i>Circulation Research</i> , 85: 931-939 (1999)	
	23	FRIEDMAN S., et al., "Hepatic lipocytes: the principal collagen-producing cells of normal rat liver," <i>Proc. Natl. Acad. Sci. USA</i> , 82(24):8681-8685 (1985)	
	24	FRIEDMAN S., et al., "Modulation of transforming growth factor preceptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and <i>in vivo</i> ," <i>J. Biol. Chem.</i> , 269(4):10551-10558 (1994)	
	25	FRIEDMAN S., et al., "Molecular mechanisms of hepatic fibrosis and principles of therapy," <i>J. Gastroenterol.</i> , 32(3): 424-430 (1997)	
	26	GEORGE, et al., "In vivo inhibition of rat stellate cell activation by soluble transforming growth factor p type II receptor: A potential new therapy for hepatic fibrosis," <i>Proc. Natl. Acad. Sci. USA</i> , 96(22):12719-24 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10,575,049	
			Filing Date	April 5, 2006	
			First Named Inventor	David De Kretser	
			Art Unit	1644	
			Examiner Name	Maher M. Haddad	
Sheet	4	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	27	HARADA K., et al., "Serum immunoreactive activin A levels in normal subjects and patients with various diseases," <i>J. Clin. Endocrinol. Metab.</i> , 81(6):2125-2130 (1996)	
	28	HUANG X., et al., "Expression changes of activin A in the development of hepatic fibrosis," <i>World Journal of Gastroenterology</i> , 7:37-41 (2001) (abstract)	
	29	HUANG X., et al., <i>Zhonghua Ganzangbing Zazhi (Chinese J. of Hepatology)</i> , 10(2):85-89 (2002) (abstract)	
	30	HUBNER G., et al., "Activin A- a novel player and inflammatory marker in inflammatory bowel disease," <i>Lab. Invest.</i> , 77:311-318 (1977)	
	31	HULLY J.R., et al., "Induction of apoptosis in the murine liver with recombinant human activin A," <i>Hepatology</i> , 20: 854-862 (1994)	
	32	INOUE S., et al., "Expression of follistatin, an activin-binding protein, in vascular smooth muscle cells and arteriosclerotic lesions," <i>Arteriosclerosis and Thrombosis</i> , 13(12):1859-1864 (1993)	
	33	KAY M., et al., "Liver regeneration: prospects for therapy based on new technologies," <i>Molecular Medicine Today</i> , 108-115 (1997)	
	34	KOGAWA K., et al., "Immunohistochemical localization of follistatin in rat tissues," <i>Endocrinol. Japan</i> , 38(4): 383-391 (1991)	
	35	KOGURE K., et al., "A single intraportal administration of follistatin accelerates liver regeneration in partially hepatectomized rats," <i>Gastroenterology</i> , 108(4):1136-1142 (1995)	
	36	KOGURE K., et al., "Immediate onset of DNA synthesis in remnant rat liver after 90% hepatectomy by an administration of follistatin," <i>J. Hepatol.</i> , 29(6):977-984 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10,575,049
				Filing Date	April 5, 2006
				First Named Inventor	David De Kretser
				Art Unit	1644
				Examiner Name	Maher M. Haddad
Sheet	5	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	37	KOGURE K., et al., "Intravenous administration of follistatin: delivery to the liver and effect on the liver regeneration after partial hepatectomy," <i>Hepatology</i> , 24(2):361-366 (1996)	
	38	KOGURE K., et al., "The role of activin and transforming growth factor β in the regulation of organ mass in the rat liver," <i>Hepatology</i> , 31(4):916-921 (2000)	
	39	KOJIMA I., et al., "Role of the activin-follistatin system in the morphogenesis and regeneration of the renal tubules," <i>Molecular and Cellular Endocrinology</i> , 180:179-182 (2001)	
	40	KOTSUJI T., et al., "Effects of activin A on the growth of neurofibroma-derived cells from a patient with neurofibromatosis type I," <i>Dermatology</i> , 201:277 (2000)	
	41	KOZAKI K., et al., "Activin/follistatin and atherosclerosis - A review," <i>J. Atherosclerosis and Thrombosis</i> , 5:36-40 (1998)	
	42	KOZIAN D., et al., "The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis," <i>Lab. Invest.</i> , 76(2): 267-276 (1997)	
	43	LAPING N., "Therapeutic uses of smad protein inhibitors: selective inhibition of specific TGF- β activities," <i>Drugs</i> , 2: 907-914 (1999)	
	44	LEE D., et al., "The hepatitis B virus encoded oncoprotein pX amplifies TGF- β family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis," <i>Genes & Dev.</i> , 15(4): 455-466 (2001)	
	45	MAESHIMA A., et al., "Hepatocyte growth factor induces branching tubulogenesis in MDCK cells by modulating the activin-follistatin system," <i>Kidney International</i> , 58:1511-1522 (2000)	
	46	MATSUDA Y., et al., "Preventative and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis," <i>Hepatology</i> , 26(1):81-89 (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10,575,049	
			Filing Date	April 5, 2006	
			First Named Inventor	David De Kretser	
			Art Unit	1644	
			Examiner Name	Mahe M. Haddad	
Sheet	6	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	47	MICHALOPOULOS G., et al., "Liver Regeneration," <i>Science</i> , 276:60-66 (1996)	
	48	MOLLOY C., et al., "Novel cardiovascular actions of the activins," 1. <i>Endocrin.</i> 161:179-185 (1995)	
	49	MUNZ B., et al. "A novel role of activin in inflammation and repair," 1. <i>Endocrin.</i> , 161:187-193,(1995)	
	50	NAKAMURA T., et al., "Inhibition of transfecting growth factor p prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats," <i>Hepatology</i> , 32(2):247-255 (2000)	
	51	NIETO N., et al., "CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells," <i>Hepatology</i> , 30(4):987-996 (1999)	
	52	OGAWA K., et al., "Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages," <i>J. Immunol.</i> , 165:2997-3003 (2000)	
	53	OHGA E., et al., "Activin receptors are expressed on human lung fibroblast and activin A facilitates fibroblast-mediated collagen gel contraction," <i>Life Sciences</i> , 66:1603-1613 (2000)	
	54	OHGA E., et al., "Effects of Activin A on Proliferation and Differentiation of Human Lung Fibroblasts," <i>Biochemical and Biophysical Research Communications</i> , 228(2):391-396 (1996)	
	55	OKUNO M., et al., "Prevention of Rat Hepatic Fibrosis by the Protease Inhibitor, Camostat Mesilate, via Reduced Generation of Active TGF- β ," <i>Gastroenterology</i> , 120(7):1784-1800 (2001)	
	56	PATELLA S., et al. "Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis." <i>J. Hepatol.</i> , 34(4):576-583, (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10,575,049	
			Filing Date	April 5, 2006	
			First Named Inventor	David De Kretser	
			Art Unit	1644	
			Examiner Name	Mahe M. Haddad	
Sheet	7	of	13	Attorney Docket Number	PARA003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	57	PHILLIPS DJ., et al., "A sensitive and specific <i>in vitro</i> bioassay for activin using a mouse plasmacytoma cell line, MPC-II," <i>J. Endocrin.</i> , 162(1):111-116 (1999)	
	58	PIANKO S., et al., "Hepatocyte apoptosis is increased in chronic HCV infection and alcohol use," Abstract from Annual Meeting of American Gastroenterological Association and American Association for the Study of Liver Diseases, 11-14 May 1997	
	59	PINZANI M., et al., "Transferring growth factor-p I regulates platelet-derived growth factor receptor p subunit in human liver fat-storing cells," <i>Hepatology</i> , 21(1):232-239 (1995)	
	60	PIRISI M., et al. "Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma," <i>Cancer Detect & Prev.</i> , 24(2):150-155 (2000)	
	61	QI Z., et al., "Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat," <i>PNAS</i> , 96:2345-2349 (1999)	
	62	RAMM G., et al., "Vitamin A-poor lipocytes: a novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts," <i>Am. J. Physiol.</i> , 269(4 Pt 1):G532-41 (1995)	
	63	RITVOS O., et al., "Activin disrupts epithelial branching morphogenesis in developing glandular organs of the mouse," <i>Mech. & Devel.</i> , 50:229-245 (1995)	
	64	ROSENBAUM J., et al., "Fibroblast growth factor 2 and transforming growth factor β 1 interactions in human liver myofibroblasts," <i>Gastroenterology</i> , 109(6):1986-1996 (1995)	
	65	SAKURAI T., et al., "Activin stimulates mitogenesis in Swiss 3T3 fibroblasts without activation of mitogen-activated protein kinases," <i>J. Biol. Chem.</i> , 269: 14118-22 (1994)	
	66	SCHWALL R., et al., "Activin induces cell death in hepatocytes <i>in vivo</i> and <i>in vitro</i> ," <i>Hepatology</i> , 18(2):347-356 (1993)	

Examiner Signature	/Mahe Haddad/	Date Considered	09/15/2011
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/